Found: 37
Select item for more details and to access through your institution.
Marginal zone lymphoma: 2023 update on diagnosis and management.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 10, p. 1645, doi. 10.1002/ajh.27058
- By:
- Publication type:
- Article
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 9, p. 894, doi. 10.1002/ajh.24429
- By:
- Publication type:
- Article
Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 4, p. 386, doi. 10.1111/ejh.13915
- By:
- Publication type:
- Article
Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency.
- Published in:
- Acta Haematologica, 2013, v. 130, n. 4, p. 254, doi. 10.1159/000351048
- By:
- Publication type:
- Article
Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. 370, doi. 10.1016/j.clml.2023.01.014
- By:
- Publication type:
- Article
IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S404, doi. 10.1016/S2152-2650(21)01912-1
- By:
- Publication type:
- Article
CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S315, doi. 10.1016/S2152-2650(21)01746-8
- By:
- Publication type:
- Article
Poster: IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01537-8
- By:
- Publication type:
- Article
Poster: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S221, doi. 10.1016/S2152-2650(21)01392-6
- By:
- Publication type:
- Article
Oral Abstract: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01273-8
- By:
- Publication type:
- Article
Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
- Published in:
- EJHaem, 2024, v. 5, n. 2, p. 325, doi. 10.1002/jha2.870
- By:
- Publication type:
- Article
All is not lost - the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab.
- Published in:
- European Journal of Haematology, 2013, v. 91, n. 2, p. 189, doi. 10.1111/ejh.12138
- By:
- Publication type:
- Article
Primary gastric diffuse large B‐cell lymphoma: A multicentre retrospective study.
- Published in:
- British Journal of Haematology, 2024, v. 205, n. 2, p. 534, doi. 10.1111/bjh.19470
- By:
- Publication type:
- Article
Chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 5, p. 701, doi. 10.1111/bjh.19095
- By:
- Publication type:
- Article
Outcomes of human immunodeficiency virus‐associated Burkitt lymphoma and diffuse large B‐cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 5, p. 865, doi. 10.1111/bjh.18704
- By:
- Publication type:
- Article
The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 1, p. 15, doi. 10.1111/bjh.17404
- By:
- Publication type:
- Article
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 6, p. 1049, doi. 10.1111/bjh.16946
- By:
- Publication type:
- Article
Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 3, p. 409, doi. 10.1111/bjh.15965
- By:
- Publication type:
- Article
Stage I Non‐Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 2, p. 334, doi. 10.1111/bjh.15444
- By:
- Publication type:
- Article
Dose adjusted- EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 3, p. 503, doi. 10.1111/bjh.14226
- By:
- Publication type:
- Article
Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 5, p. 876, doi. 10.1111/bjh.14325
- By:
- Publication type:
- Article
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 3, p. 531, doi. 10.1111/bjh.13863
- By:
- Publication type:
- Article
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 1, p. 80, doi. 10.1111/bjh.13796
- By:
- Publication type:
- Article
A consensus statement on the use of biosimilar medicines in hematology in Australia.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2020, v. 16, n. 4, p. 211, doi. 10.1111/ajco.13337
- By:
- Publication type:
- Article
Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
- Published in:
- Internal Medicine Journal, 2024, v. 54, n. 8, p. 1384, doi. 10.1111/imj.16454
- By:
- Publication type:
- Article
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic.
- Published in:
- Internal Medicine Journal, 2020, v. 50, n. 6, p. 667, doi. 10.1111/imj.14859
- By:
- Publication type:
- Article
Author reply.
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
Front‐line management of indolent non‐Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
- Published in:
- Internal Medicine Journal, 2019, v. 49, n. 9, p. 1070, doi. 10.1111/imj.14268
- By:
- Publication type:
- Article
Front‐line management of non‐Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
- Published in:
- Internal Medicine Journal, 2019, v. 49, n. 4, p. 422, doi. 10.1111/imj.14113
- By:
- Publication type:
- Article
Comment on "Drug-induced thrombocytopenia: an updated systematic review".
- Published in:
- 2009
- By:
- Publication type:
- commentary
Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results From a Phase 2 Study.
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. A, p. 44
- By:
- Publication type:
- Article
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study.
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. A, p. 33
- By:
- Publication type:
- Article
Bone Marrow Biopsy for the Initial Staging of Patients With Lymphoma: Too Soon to Toss the Trephine.
- Published in:
- Oncology (08909091), 2013, v. 27, n. 12, p. 1288
- By:
- Publication type:
- Article
IgG4-related disease with cutaneous manifestations treated with rituximab: Case report and literature review.
- Published in:
- Australasian Journal of Dermatology, 2014, v. 55, n. 2, p. 132, doi. 10.1111/ajd.12100
- By:
- Publication type:
- Article
Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies.
- Published in:
- Journal of Personalized Medicine, 2021, v. 11, n. 8, p. 764, doi. 10.3390/jpm11080764
- By:
- Publication type:
- Article
Synchronous biphenotypic Richter syndrome with Epstein-Barr virus-positive nodal classical Hodgkin lymphoma and bone marrow diffuse large B-cell lymphoma.
- Published in:
- Histopathology, 2016, v. 69, n. 4, p. 707, doi. 10.1111/his.12984
- By:
- Publication type:
- Article
A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma.
- Published in:
- Clinical Epigenetics, 2023, v. 15, n. 1, p. 1, doi. 10.1186/s13148-023-01427-7
- By:
- Publication type:
- Article